未名医药(002581) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net loss of between 23 million and 42 million yuan for the first half of 2024, compared to a loss of 53.76 million yuan in the same period last year[2] - The net profit attributable to shareholders is projected to be a loss of between 20.4 million and 39.4 million yuan, an improvement from a loss of 48.14 million yuan year-over-year[2] - Basic earnings per share are expected to be a loss of between 0.0349 yuan and 0.0637 yuan, compared to a loss of 0.0815 yuan in the previous year[2] Reasons for Loss - The company attributes the loss to decreased investment income and plans to explore new product application areas to adapt to market changes[4] Cost Management - The company is implementing cost reduction and efficiency enhancement measures to improve internal effectiveness[4] Financial Reporting - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 semi-annual report[5]